OmicsHQ brings together comprehensive, expertly curated, standardized multi-omics datasets from across the scientific ecosystem, complete with pre-processed datasets ready to accelerate research, drug-discovery, and AI-driven innovation.

Rancho BioSciences, the premier tech-enabled data science partner for biopharma, announced the launch of OmicsHQ^TM, a unified catalog of expertly curated, standardized multi-omics datasets designed for immediate use in research, drug discovery, and AI/ML model development. The company is launching the product at BioIT World Conference & Expo, May 19, 2026, Boston, MA.

"OmicsHQ represents our commitment to removing the barriers that slow scientific progress," said Chris O'Brien, CEO of Rancho Biosciences. "By unifying fragmented data sources into a single, curated catalog with consistent standards, we are enabling researchers to move from search to analysis in a fraction of the time. This is multi-omics data excellence at scale, and it is available at scientists' fingertips starting today."

Analysis-and AI-Ready Data, From Day One
Today, multi-omics data is scattered across dozens of repositories, inconsistently annotated, and rarely ready for downstream analysis without significant manual effort. OmicsHQ^TM changes that.

At launch, OmicsHQ^TM provides researchers with a single, searchable catalog of single-cell transcriptomics data, including over 1,000 preprocessed datasets ready for immediate use, and more than 8,000 additional studies available for on-demand processing. All datasets undergo a rigorous multi-step curation workflow. Every dataset is prescreened for completeness, harmonized against standard ontologies (UBERON, DOID, EFO, MESH, NCIT), processed through a reproducible bioinformatics pipeline, and independently quality-reviewed. Datasets are available for download in H5AD and Seurat formats, with no additional preprocessing or harmonization required. Additional data modalities will continue to be added over time.

Researchers can visualize UMAP and PCA embeddings, explore gene expression, and evaluate quality control metrics directly within the platform before downloading, making it easier to identify the right dataset before committing time and compute resources.

"The industry is at an inflection point where data has the power to drive truly innovative therapeutic strategies, but only when that data is trustworthy," said Julie Bryant, Founder and Chief Strategy Office of Rancho BioSciences. "Context, curation, and harmonization are what transform raw data into something scientists can actually act on. OmicsHQ^TM was built on that principle, and we are excited to put that foundation to work for organizations focused on improving human health."